Brief: GSK Says China Approves Nucala For HES Treatment

GSK

Tue 12:03

June 23 (Reuters) - GSK plc GSK.L:
SAYS NUCALA APPROVED IN CHINA FOR TREATMENT OF HYPEREOSINOPHILIC SYNDROME IN ADULTS AND ADOLESCENTS 12 AND OLDER  
Source text
 

 (Reporting by Beijing Newsroom)
 ((Shi.Bu@thomsonreuters.com;))